Gilead Sciences Announces First Quarter 2015 Financial Results

Go back to Gilead Sciences Announces First Quarter 2015 Financial Results

Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech Pick

May 1, 2015 7:10 AM EDT

Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $116.00) after the company "crushed" the quarter and raised its outlook.

Schimmer commented, "GILD hosted the 1Q earnings call after the... More

Gilead Sciences (GILD) Bullish Stance Reiterated at Baird on 'Beat and Raise' Q1

May 1, 2015 6:42 AM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and $126 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q1.

Skorney commented, "A sizeable beat should be enough to support the stock and perhaps stop the sector slide. We expect... More

Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; 1.7% Yield

April 30, 2015 5:21 PM EDT

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.

The dividend will be payable on June 29, 2015, to stockholders of record on June 16, 2015, with an ex-dividend date of June 12, 2015.

The annual yield on the dividend is 1.7... More

Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance

April 30, 2015 4:02 PM EDT

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.76, $0.48 better than the analyst estimate of $2.28. Revenue for the quarter came in at $7.59 billion versus the consensus estimate of $6.81 billion.

Gilead Sciences sees FY2015 revenue of $28-29 million, versus the consensus of $28.50... More